|
Acute dyspnea
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Our main aim was to study the association between plasma endostatin and 90-day mortality in an unselected cohort of patients admitted to the ED for acute dyspnea.
|
31672650 |
2020 |
|
Cardiovascular morbidity
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Increased levels of circulating endostatin predicts cardiovascular morbidity and impaired kidney function in the general population.
|
31672650 |
2020 |
|
Congenital arteriovenous malformation
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, serial measurements of serum VEGF and endostatin after SRS might help predict RICs in patients with arteriovenous malformation treated by SRS.
|
30831282 |
2019 |
|
Coronary Arteriosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Raised levels of serum endostatin might be associated with cardiovascular events in patients with stable coronary heart disease.
|
30959314 |
2019 |
|
Coronary heart disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Raised levels of serum endostatin might be associated with cardiovascular events in patients with stable coronary heart disease.
|
30959314 |
2019 |
|
Diabetic Nephropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Urinary chemokine C-X-C motif ligand 16 and endostatin as predictors of tubulointerstitial fibrosis in patients with advanced diabetic kidney disease.
|
31598726 |
2019 |
|
Glomerulonephritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Endostatin and blood urea nitrogen (BUN) concentration were measured in mice with a glomerulonephritis phenotype.
|
31404120 |
2019 |
|
Glycogen storage disease type II
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
AMD was an independent factor associated with lower levels of angiogenin (β = -0.29, <i>p</i> < 0.001), endostatin (β = -0.18, <i>p</i> < 0.001), FGF-basic (β = -0.18, <i>p</i> < 0.001), PlGF (β = -0.24, <i>p</i> < 0.001), miRNA-21-3p (β = -0.13, <i>p</i> = 0.01) and miRNA-155-5p (β = -0.16, <i>p</i> = 0.002); and with higher levels of FGF-acidic (β = 0.11, <i>p</i> = 0.03), miRNA-23a-3p (β = 0.17, <i>p</i> < 0.001), miRNA-126-5p (β = 0.13, <i>p</i> = 0.009), miRNA-16-5p (β = 0.40, <i>p</i> < 0.001), miRNA-17-3p (β = 0.13, <i>p</i> = 0.01), miRNA-17-5p (β = 0.17, <i>p</i> < 0.001), miRNA-223-3p (β = 0.15, <i>p</i> = 0.004), and miRNA-93 (β = 0.11, <i>p</i> = 0.04).
|
31731799 |
2019 |
|
Irritable Bowel Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Mean H-scores for endostatin expression were higher in the active UC group than in the inactive UC and IBS groups, in the stroma and endothelium.
|
30892485 |
2019 |
|
Takayasu Arteritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
To investigate serum levels of a panel of angiogenic inducers (VEGF, FGF-2, Angiopoietin 1, -2, soluble VCAM-1) and inhibitors (angiostatin, endostatin, pentraxin-3) in patients with giant cell arteritis (GCA) and Takayasu's arteritis (TAK), in order to gain further insights into the molecular mechanisms driving angiogenesis dysregulation in large-vessel vasculitis (LVV).
|
31573481 |
2019 |
|
Giant Cell Arteritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Anti-angiogenic factor (Angiostatin, Endostatin, PTX3) serum levels were significantly higher in both GCA and TAK patients compared to NC.
|
31573481 |
2019 |
|
Tuberous Sclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Serum endostatin levels are associated with diffusion capacity and with tuberous sclerosis- associated lymphangioleiomyomatosis.
|
30922357 |
2019 |
|
Rubeosis iridis
|
0.010 |
Biomarker
|
disease |
BEFREE |
UPARANT is an effective antiangiogenic agent in a mouse model of rubeosis iridis.
|
31243519 |
2019 |
|
Exfoliation Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of Aqueous Endocan and Endostatin Levels in Patients With Pseudoexfoliation Syndrome.
|
30339555 |
2019 |
|
Metastatic osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The addition of perioperative rh-endostatin to chemotherapy could significantly improve the DMFS and OS of patients with non-metastatic osteosarcoma.
|
31119057 |
2019 |
|
Metastatic melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Endostatin and Gal3BP may represent prognostic biomarkers for patients on ipilimumab treatment in metastatic melanoma and should be further evaluated.
|
30821848 |
2019 |
|
Arteriovenous hemangioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, serial measurements of serum VEGF and endostatin after SRS might help predict RICs in patients with arteriovenous malformation treated by SRS.
|
30831282 |
2019 |
|
Bronchobiliary fistula
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
This is the first report of BBF after administration of the new antiangiogenic agent ramucirumab.
|
31624752 |
2019 |
|
Sleep Apnea, Obstructive
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study aims to evaluate the influence of intermittent hypoxia (IH), a novel hallmark of OSA, on tumor and to access the anti-tumor effect of endostatin on a mouse model with OSA.
|
30293229 |
2019 |
|
Lymphangioleiomyomatosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Endostatin levels were associated with DLCO and were higher in subjects with TSC-associated LAM compared to sporadic LAM.
|
30922357 |
2019 |
|
Arteriovenous Malformations, Cerebral
|
0.010 |
Biomarker
|
group |
BEFREE |
Do Serum Vascular Endothelial Growth Factor and Endostatin Reflect Radiological Radiation-Induced Changes After Stereotactic Radiosurgery for Cerebral Arteriovenous Malformations?
|
30831282 |
2019 |
|
Intracortical osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to determine whether the addition of perioperative rh-endostatin to chemotherapy could improve the probability of distant metastasis-free survival (DMFS) and overall survival (OS) in patients newly diagnosed with non-metastatic conventional osteosarcoma.
|
31119057 |
2019 |
|
HEMIHYPERPLASIA, ISOLATED
|
0.010 |
Biomarker
|
disease |
BEFREE |
Microvessel density (MVD) and vascular endothelial growth factor (VEGF) were determined for evaluating the anti-tumor effect of endostatin among the normoxia and IH conditions.
|
30293229 |
2019 |
|
Tubulointerstitial fibrosis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Urinary chemokine C-X-C motif ligand 16 and endostatin as predictors of tubulointerstitial fibrosis in patients with advanced diabetic kidney disease.
|
31598726 |
2019 |
|
Experimental Organism Basal Cell Carcinoma
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Therefore, endostatin can inhibit the proliferation, invasion and EMT in BCC.
|
30720196 |
2019 |